Aurigene announces the exercise of curis’ option for CA-327 (PD-L1/tim-3 small molecule antagonist), the third program under its collaboration, license and option agreement of January, 2015

Aurigene a discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases, announced today the nomination of the development candidate and exercising of the option